Letter: The World Health Organization's Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022-2031

Kanmounye, Ulrick Sidney; Abu-Bonsrah, Nancy; Shlobin, Nathan A.; Djoutsop, Olga Mbougo

doi:10.1227/neu.0000000000001976

Cited by 21 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…sion as a WHO priority within its "Intersectoral Global Action Plan for Epilepsy and Other Neurological Disorders 2022-2031." 32,33 While not included in our survey, epilepsy surgery offers a means to reduce seizure frequency and the need for seizure medications. 34,35…”

Section: Data Evaluationmentioning

confidence: 99%

Mapping the global neurosurgery workforce. Part 1: Consultant neurosurgeon density

Gupta,

Gal,

Athni

et al. 2024

Journal of Neurosurgery

View full text Add to dashboard Cite

OBJECTIVE It is unknown whether efforts to expand access to neurosurgery worldwide have translated to an increase in the global neurosurgery workforce, particularly in low- and middle-income countries. The main objective of this study was to quantify the number and distribution of consultant neurosurgeons worldwide, while also identifying temporal and geographic trends in the neurosurgery workforce in different income levels and WHO regions, and analyzing what factors might contribute to the growth of a national workforce. METHODS This study was a subanalysis of an electronic cross-sectional survey administered to participants identified through neurosurgery societies, personal contacts, and online searches of all 193 countries and 26 territories, independent states, and disputed regions as defined by the World Bank (WB) and United Nations between October 2022 and March 2023. Population-weighted statistics for the consultant neurosurgery workforce and resource availability were estimated, and linear regression analysis was conducted to identify correlations with growth in the workforce. RESULTS Data were obtained for 192 countries (99.5%) and 25 additional territories, states, and disputed regions (96.2%). One hundred seventy-seven respondents participated in the survey. There were an estimated 72,967 neurosurgeons worldwide, representing a global pooled density of 0.93 neurosurgeons per 100,000 people and a median country density of 0.44 neurosurgeons per 100,000 people. The authors found an increasing density of consultant neurosurgeons, from low-income countries (0.12 per 100,000 people), to lower-middle-income countries (LoMICs; 0.37), to upper-middle-income countries (UpMICs; 1.13), and to high-income countries (2.44). The WHO African and Southeast Asia regions had the lowest pooled neurosurgeon density, while the Western Pacific region (WPR) had the highest density. There were 29 countries, 14 territories, and 1 independent state with no neurosurgeons. Neurosurgeons in countries with higher income–level designations had more frequent access to resources and equipment. The annual growth rates in workforce density were highest in LoMICs (26.0%) and UpMICs (21.3%), and the most rapid annual growth was in the Southeast Asia region (33.0%). Regression analysis revealed that an increasing population quartile, the Eastern Mediterranean region (relative to the WPR), the presence of a national neurosurgery society, increasing global development aid, and national gross domestic product were associated with relative growth in national neurosurgeon density. CONCLUSIONS The authors estimate a global consultant neurosurgeon workforce of nearly 73,000 neurosurgeons, with stark disparities in the density and growth of the workforce in different WB income-level groups and WHO regions. The presence of a neurosurgery society was correlated with the growth of the workforce, and this study identified several regional targets for further intervention to expand access to neurosurgery.

show abstract

Section: Data Evaluationmentioning

confidence: 99%

Mapping the global neurosurgery workforce. Part 1: Consultant neurosurgeon density

Gupta,

Gal,

Athni

et al. 2024

Journal of Neurosurgery

View full text Add to dashboard Cite

show abstract

“…The action plan aims to reduce and eliminate preventable deaths caused by E and other neurological disorders, to improve access to promotion, prevention, management and care services, decreasing stigma and discrimination and protecting the human rights of people with neurological disorders. This action plan promotes physical and mental health, prevention, early diagnosis, assistance, treatment and rehabilitation, along with social, economic and educational needs and necessity of inclusion for people with E or different neurological diseases and their family ( 28 ).…”

Section: Premisesmentioning

confidence: 99%

Governance of the clinical pathway and management of the patient suffering from epilepsy and drug-resistant epilepsy

Neve

Falcicchio

2022

Grhta

View full text Add to dashboard Cite

Epilepsy is a diffuse chronic neurological disease affecting around 50 million people worldwide. The diagnostic criteria by the International League against Epilepsy must be fulfilled to diagnose the disease, which is characterized by brief and transient episodes of abnormal neuronal activity involving one or both hemispheres, depending on the epilepsy type. The diagnosis of epilepsy should be properly and timely made because patients suffering from the disease are affected not only by seizure recurrence but also by epilepsy-related psychiatric and/or cognitive comorbidities that may have a huge impact with severe professional and social implications. It is of vital importance to define a specific governance model that has to be virtuously applied into the different phases of the clinical pathway of the patients with epilepsy in order to guarantee them the best model of care possible.

show abstract

“…Epilepsy is a chronic non-communicable neurological disorder characterized by recurrent and spontaneous epileptic seizures. Epilepsy affects more than 51 million individuals across the globe and every year more than 4.9 million people develop new-onset epilepsy, establishing its status as one of the prevalent neurological disorders on a global scale [ 1 ]. Epilepsy is marked by recurring seizures, a higher mortality rate, and reduced engagement in social activities and overall quality of life.…”

Section: Introductionmentioning

confidence: 99%

Circulating miRNAs as Novel Clinical Biomarkers in Temporal Lobe Epilepsy

Guarnieri,

Amodio,

Bosco

et al. 2024

ncRNA

View full text Add to dashboard Cite

Temporal lobe epilepsy (TLE) represents the most common form of refractory focal epilepsy. The identification of innovative clinical biomarkers capable of categorizing patients with TLE, allowing for improved treatment and outcomes, still represents an unmet need. Circulating microRNAs (c-miRNAs) are short non-coding RNAs detectable in body fluids, which play crucial roles in the regulation of gene expression. Their characteristics, including extracellular stability, detectability through non-invasive methods, and responsiveness to pathological changes and/or therapeutic interventions, make them promising candidate biomarkers in various disease settings. Recent research has investigated c-miRNAs in various bodily fluids, including serum, plasma, and cerebrospinal fluid, of TLE patients. Despite some discrepancies in methodologies, cohort composition, and normalization strategies, a common dysregulated signature of c-miRNAs has emerged across different studies, providing the basis for using c-miRNAs as novel biomarkers for TLE patient management.

show abstract

Letter: The World Health Organization's Intersectoral Global Action Plan on Epilepsy and Other Neurological Disorders 2022-2031

Cited by 21 publications

References 13 publications

Mapping the global neurosurgery workforce. Part 1: Consultant neurosurgeon density

Mapping the global neurosurgery workforce. Part 1: Consultant neurosurgeon density

Governance of the clinical pathway and management of the patient suffering from epilepsy and drug-resistant epilepsy

Circulating miRNAs as Novel Clinical Biomarkers in Temporal Lobe Epilepsy

Contact Info

Product

Resources

About